GLP-1 drugs taken by 30 million Americans now carry an FDA warning for a rare ‘stroke of the eye’ that can cause vision loss

ملخص مفصل

The data on which the FDA’s warning is based suggests a real but low risk of NAION for people taking GLP-1 medications.

GLP-1 drugs must now carry a warning label about a potential link to a rare eye condition that can result in vision loss, the U.S. Food and Drug Administration announced on Nov. 9. 2026. The eye condition is called non-arteritic anterior ischemic optic neuropathy, or NAION, and doctors often refer to it as a stroke of the eye.

I am a clinician and epidemiologist who has studied GLP-1 drugs, and my colleagues and I published one of the studies that identified a link between GLP-1 drugs and NAION.

Millions of people around the world take these medications – including 30 million in the U.S. – to treat diabetes and obesity and reduce the risk of cardiovascular disease. They are also being investigated for an expanding list of clinical conditions.

The data on which the FDA’s warning is based suggests a real but low risk of NAION for people taking GLP-1 medications. This is not a trivial or inconsequential outcome for those who develop the eye stroke. But on balance, if you’re using the medication for an FDA-approved condition such as diabetes or obesity on the advice of your doctor, the risk should not deter you from doing so.

Here’s what patients who use GLP-1 drugs need to know about this rare but serious side effect.

NAION is an injury to the optic nerve, which is the nerve that connects the eye to the brain. This eye condition is caused by a sudden reduction in blood flow. Without enough blood flow, patients may experience sudden, painless blurry vision, dark patches, partial loss of vision or even blindness.

These symptoms generally persist and often lead to permanent visual impairment. Patients often notice these symptoms first thing in the morning when they wake up, as it tends to happen more frequently at night when blood pressure is naturally lower.

As use of GLP-1 drugs increased – particularly since 2021, when they were approved for obesity – cases of NAION began to emerge.

To determine that the connection was strong enough to merit a warning, the FDA first compiled…

مطلع المقال، مقتطف من Fortune. لقراءة المقال كاملًا، افتحه على موقع الناشر.